Articles |
From the Center for Anesthesiology Research (D.S.D., A.D., W.S., C.S.M.) and the Department of Molecular Cardiology (L.A.M., M.B.), Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio.
Correspondence to Meredith Bond, PhD, Department of Molecular Cardiology/FF10, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195.
| Abstract |
|---|
|
|
|---|
Key Words: myocytes arachidonic acid endothelin-1 phosphorylation myofilaments
| Introduction |
|---|
|
|
|---|
We previously showed that both AA and endothelin-1 (ET) increase action potential duration via protein kinase C (PKC)dependent inhibition of the transient outward K+ current (Ito) and PKC-dependent inhibition of the delayed rectifier K+ current (IK), respectively.2 We also demonstrated that the positive inotropic effect of ET was inhibited by the PKC antagonist staurosporine. In isolated perfused hearts, ET has been shown to stimulate both phospholipase C6 and phospholipase A2,7 releasing diacylglycerol (DG) and AA, respectively. Both DG and AA are activators of PKC, acting synergistically in some cell types.8
Activation of PKC in cardiac muscle cells by phorbol esters has been
shown to phosphorylate myofibrillar proteins,9 10 11 12
resulting in changes in the sensitivity of the myofilaments to
Ca2+11 and/or changes in
Vmax of the actomyosin ATPase.9 This is
consistent with the finding that phorbol esters and
-adrenergic
agonists stimulate translocation of some PKC isoforms to the
myofilaments in cultured neonatal cardiac myocytes,13
whereas other isoforms were shown to translocate to sarcolemmal,
perinuclear, or intranuclear regions.14 In adult rat
ventricular myocytes, phorbol esters have been reported to stimulate
translocation of the
,
, and
isoforms of PKC to the
particulate fraction,15 whereas ET and
-adrenergic
agonists16 stimulate translocation of the
isoform to
the membrane fraction, although the intracellular site(s) of
translocation was not determined.15 16 In addition,
myocardial ischemia, a condition known to cause accumulation of
unesterified AA17 and increased expression of ET
receptors,18 results in translocation of PKC to the
membrane.19
The role of PKC activation in the regulation of cardiac contractility
remains controversial: phorbol esters are known to have pronounced
negative inotropic effects20 21 in contrast to the
well-established positive inotropic effect of ET22 or
-adrenergic agonists,23 which are also known activators
of PKC. However, positive inotropic effects of phorbol esters at
extremely low concentrations (<1 nmol/L) have also been observed,
suggesting perhaps selective activation of specific PKC
isoforms.24 25 PKC-dependent phosphorylation of
Ca2+ channels,26
phospholamban,27 the cardiac ryanodine
receptor,28 and the SR
Ca2+-ATPase29 has been demonstrated and
may also play a role in mediating inotropic responses in the heart.
Therefore, biologically active compounds that activate PKC in cardiac
muscle may be involved in the modulation of cardiac contractility via
phosphorylation-dependent regulation of the contractile machinery
itself and/or phosphorylation of Ca2+ regulatory
proteins.
Previous studies examining PKC-dependent phosphorylation of myofibrillar proteins have generally focused on isolated myofibrils or permeabilized myocytes.9 10 11 12 In the present study, we used intact ventricular myocytes to investigate the effects of AA on cardiac excitation-contraction coupling. Specifically, we investigated whether AA stimulates phosphorylation of myofibrillar proteins in isolated ventricular myocytes. We also investigated whether ET stimulates phosphorylation of cardiac myofibrillar proteins, since ET is known to activate phospholipase C, causing release of DG, an endogenous activator of PKC.6 30 The results of this study present the novel findings that both AA and ET stimulate phosphorylation of troponin I (TnI) and myosin light chain 2 (MLC2) in isolated ventricular myocytes.
| Materials and Methods |
|---|
|
|
|---|
Fura 2 Experiments
Freshly isolated ventricular myocytes suspended in oxygenated
HBS (12 mL, 5x105 cells per milliliter) were divided into
equal portions (6 mL each) and allowed to settle by gravity on the
bench. The supernatant was aspirated, and half was resuspended in 6 mL
of KHB, with the other half in 6 mL of KHB lacking
Ca2+. The cells were washed a second time to ensure
removal of all extracellular Ca2+ and again pelleted
and resuspended in the appropriate buffer. The cell suspensions were
placed under 100% O2 and incubated while gently shaking at
room temperature for 1.5 hours, at which time 5 µmol/L fura 2-AM was
added to the cells, and the incubation was allowed to continue for an
additional 45 minutes. The cells were washed in their respective
buffers (ie, KHB±Ca2+) to remove extracellular fura
2-AM and resuspended in oxygenated KHB or KHB lacking added
Ca2+. Fluorescence measurements, designed to examine
the size of intracellular Ca2+ stores, were
performed in populations of myocytes as previously
described.2 Briefly, 75 µL of the fura 2loaded cells
(
1.5x105 cells) were added to the cuvette in 2 mL of
the appropriate buffer (KHB or KHB lacking added
Ca2+, 37°C). EGTA was added to the cuvette
to eliminate any potential contribution of extracellular
Ca2+ to the fluorescence signal. Once the
fluorescence signal had stabilized, ionomycin was added to the cuvette
to release Ca2+ from intracellular stores. The
amplitude of the Ca2+ transient, evoked by addition
of ionomycin to cells that had been incubated in KHB, was compared with
the amplitude of the Ca2+ transient evoked by
addition of ionomycin to cells that had been incubated in
Ca2+-free KHB.
Labeling of Myofibrils in Intact Ventricular Myocytes With
[32P]Orthophosphate
Phosphorylation of myofibrils in intact rat ventricular myocytes
by [32P]orthophosphate (32Pi) was
performed by using modifications of previously described
methods.9 32 Isolated ventricular myocytes from one rat
heart were suspended in 15 mL of phosphate-free HBS (5x105
cells per milliliter) and incubated with 250 µCi of
32Pi for 2 hours at room temperature. The cell
suspension was gently shaken and maintained under 100% O2
throughout the entire labeling period. There was no significant loss in
myocyte viability (percentage of rod-shaped cells) after the 2-hour
incubation period with 32Pi.
After the labeling period, the cells were pelleted and resuspended in phosphate-free KHB in the presence or absence of extracellular Ca2+, divided into 2-mL aliquots, and placed in test tubes with or without calphostin C (1 µmol/L).33 To ensure that the cells remained viable and maximally oxygenated throughout the incubation, all tubes were purged with 100% O2, then placed on their sides, and gently agitated for 3 minutes at 37°C in a shaking water bath. After the 3-minute preincubation, either phorbol 12-myristate 13-acetate (PMA), ET, or AA was added to the cell suspension. The phosphatase inhibitor calyculin A (1 nmol/L)34 was also added at this time, and all test tubes were again purged with O2 and incubated for an additional 10 minutes at 37°C. Controls contained either calphostin C, ethanol (solvent for AA), dimethyl sulfoxide (DMSO, solvent for calphostin C) alone, or both ethanol and DMSO in multiple agonist experiments. The final concentrations of ethanol and/or DMSO together did not exceed 0.1%.
Routinely, myocyte viability was assessed after the incubation periods to ensure that viability remained >75% after the 10-minute incubation at 37°C in the presence of the agonists and inhibitors. Calphostin C has been reported to be cytotoxic to cells at concentrations that inhibit PKC during extended incubation periods (72 hours).33 Myocyte viability was routinely between 80% and 85% before incubation with calphostin C at 37°C, and we found no significant loss of viability after the 13-minute incubation with this inhibitor (<3%) plus the added agonists. At the end of the incubation, the reactions were terminated, and agonists were removed by rapidly washing the myocytes in physiological saline (4°C, 5 mL) containing protease inhibitors (5 µg/mL pepstatin A, 10 µg/mL leupeptin, 43 µg/mL phenylmethylsulfonyl fluoride, 5 µg/mL antipain, and 5 mmol/L EGTA) and protein phosphatase inhibitors (0.1 µmol/L sodium orthovanadate and 1 nmol/L calyculin A) immediately before suspending the pellet in 2 mL of ice-cold "inhibiting buffer" (mmol/L: KH2PO4 50, NaF 70, and EDTA 5) as described by Holroyde et al.35 Myofibrils were extracted on ice for 30 minutes by adding 1% Triton X-100, plus the protease and phosphatase inhibitors listed above, to the inhibiting buffer. Detergent-extracted myofibrils were pelleted at 5000g by using an Eppendorf microcentrifuge for 5 minutes, and the supernatant was discarded. Examination of the pellet under the light microscope indicated that it was enriched in myofibrils.
SDS-PAGE
PAGE of 32P-labeled cardiac myofibrils was performed
on 12% slab gels according to Laemmli.36 The myofibrillar
pellet was solubilized and denatured in sample preparation buffer
containing 4% SDS, 0.23 mol/L 2-mercaptoethanol, and 0.2 mol/L
Tris-HCl (pH 6.5) at 100°C for 5 minutes. To standardize loading of
the gels, protein determinations of the myofibrillar
extracts37 were performed on each of the samples before
loading the gel. Protein (75 µg) was applied to each lane, and PAGE
was performed in the presence of 0.1% SDS at constant current (10 mA)
overnight (16 hours). Gels were stained with Coomassie blue, dried the
following day, and subjected to phosphor screen autoradiography for
quantification of labeled proteins. A PhosphorImager (Molecular
Dynamics, Inc) was used to quantify the amount of radioactivity in each
band. The extent of 32P incorporation into protein bands
was quantified by using the IMAGEQUANT
software package.
Western Blot Analysis of Cardiac Myofibrillar Proteins
After SDS-PAGE of myofibrillar proteins, proteins were
transferred (300 mA, 60 minutes) from the gel to a nitrocellulose
membrane.38 The remaining protein binding sites on the
nitrocellulose membrane were blocked during an overnight incubation
with 3% fish gelatin in Tris-saline buffer (pH 7.0). After blocking,
nitrocellulose membranes were incubated with rabbit anti-mouse MLC2
antibody (gift from Dr Ken Chien, University of California, San Diego)
at a dilution of 1:500 for 2 hours. In a separate experiment, the
nitrocellulose membrane containing the myofibrillar proteins was
incubated with a monoclonal antibody raised against bovine TnI (gift of
Dr Stefano Schiaffino, University of Padua, Italy) at a dilution of
1:500 for 2 hours. After three washes in Tris-saline buffer, the
nitrocellulose membranes were incubated with secondary antibody coupled
to horseradish peroxidase, at a dilution of 1:2000 for 1 hour. The
nitrocellulose membranes were then washed in Tris-saline buffer and
placed in horseradish peroxidase substrate until visible bands were
observed (1 hour).
Measurement of Myocyte Contractility Using Video Edge Detection
The effects of AA and ET on myocyte contractility were assessed
in single electrically stimulated ventricular myocytes. An aliquot of
ventricular myocytes was placed in a temperature-regulated (28°C)
chamber (Bioptechs, Inc) mounted on the stage of an Olympus CK-2
inverted microscope. The volume of the bath was 2 mL. The cells were
superfused continuously with KHB at a flow rate of 2 mL/min and
electrically stimulated through bipolar platinum electrodes at a
frequency of 0.5 Hz and duration of 5 milliseconds by using an SD9
stimulator (Grass Instruments). Either AA or ET was added to the
superfusion solution after a 1- to 2-minute equilibration period and
required 30 seconds to reach the myocytes in the chamber. Myocytes were
chosen for study according to the following criteria: (1) rod-shaped
appearance with clear striations and no membrane blebs, (2) a negative
staircase of twitch performance on stimulation from rest, and (3) the
absence of frequent (>1/min) spontaneous contractions. Measurements of
unloaded cell shortening were monitored with a video edge detector
(Crescent Electronics). Light-dark contrast at the cell end provides a
marker for measurement of the amplitude and velocity of cell motion.
DATA SPONGE software (Bioscience Analysis
Software, Ltd) was used for data acquisition and analysis of
unloaded cell shortening at a sampling rate of 500 Hz with a 60-Hz
filter.
Materials
Collagenase type II was obtained from Worthington Biochemical.
Calphostin C and staurosporine were obtained from Research
Biochemicals, Inc and were diluted in DMSO to appropriate stock
concentrations in single-use vials stored at -70°C. AA (Cayman
Chemical Co) was divided into aliquots (25 mmol/L) and diluted in
ethanol in N2-purged airtight glass vials stored at
-70°C. A fresh vial was used each day. ET (Peptides International)
was diluted into single-use vials in distilled water (100 µmol/L) and
stored at -70°C until the day of use. ET and AA were maintained on
ice for the duration of the experiment. Triton X-100, Protogel (30%
[wt/vol] acrylamide and 0.8% [wt/vol] bis-acrylamide stock
solution), and 10x electrophoresis tank buffer (0.25 mol/L Tris, 1.92
mol/L glycine, and 1% SDS) were purchased from National Diagnostics.
N,N,N',N'-Tetramethyl-ethylenediamine, protein G,
2-mercaptoethanol, ammonium persulfate, and prestained high and low
molecular weight markers were from Biorad Laboratories, Inc.
Experimental Controls and Data Analysis
Untreated controls (controlcalphostin C or
controlCa2+ rich) were normalized to 100%.
Increases in the phosphorylation of TnI and MLC2 in response to PMA,
ET, and/or AA were calculated as percent increase in 32P
incorporation (±SEM) of the respective untreated time-matched control.
After pretreatment with calphostin C, inhibition of TnI and MLC2
phosphorylation by AA, ET, or PMA was calculated as percent inhibition
of 32P incorporation (±SEM) compared with myocytes treated
with PMA, AA, or ET alone. Therefore, percent inhibition refers to
percent inhibition of the increase above basal phosphorylation. After
results of all trials from 1 day were averaged to give a single value,
comparisons between groups were performed by using Student's
t test. Differences were considered statistically
significant at P<.05. For the contractility study, the
amplitude of unloaded cell shortening before the addition of AA or ET
was compared with the amplitude of shortening after the addition of
agonist. The results are expressed as percent increase over the value
before the addition of agonist (±SEM).
| Results |
|---|
|
|
|---|
|
Effect of Phosphatase Inhibition With Calyculin A on the
32P Labeling of Cardiac Myofibrillar Proteins
Previous studies by others39 have shown that
calyculin A at a concentration of 10 nmol/L stimulates incorporation of
32P into TnI and MLC2 in cardiac muscle cells. Therefore,
in order to confirm that the 10-fold lower concentration of calyculin A
used in these experiments (1 nmol/L) had no effect on the
32P labeling of myofibrillar proteins in cardiac muscle
cells under control conditions, we investigated the dose-dependent
effects of phosphatase inhibition with calyculin A on the labeling of
cardiac myofibrillar proteins in intact ventricular myocytes. Addition
of calyculin A (1 to 2 nmol/L) for 10 minutes at 37°C had no
significant effect on the labeling of myofibrillar proteins in intact
cardiac myocytes when compared with time-matched untreated control
myocytes (Fig 2
). Small increases in the labeling of TnI
(12±5.4%) and MLC2 (10±4.8%) were observed with 5 nmol/L calyculin
A, but the increase in labeling was not significantly different from
untreated control cells (P<.1). However, significant
increases in the phosphorylation of TnI (39±6.8%) and MLC2 (48±7.3%
increase) were observed with the addition of 10 nmol/L calyculin A when
compared with untreated time-matched control cells.
|
Phosphorylation of TnI and MLC2 by PMA
Suspensions of cardiac myocytes were stimulated with PMA in order
to activate phorbol estersensitive PKC isoforms. In the absence of
calyculin A, PMA stimulated a consistent (40% to 60%) increase in TnI
phosphorylation, with no apparent effect on other myofibrillar proteins
(data not shown). However, when populations of ventricular myocytes
were treated with 1 nmol/L calyculin A and PMA together, 1.5-fold and
3-fold increases in the labeling of TnI and MLC2, respectively (Fig 1
,
lane 5), were observed when compared with calyculin Atreated
unstimulated control myocytes (Fig 1
, lane 3). Small,
insignificant increases in phosphorylation of TnT and tropomyosin were
occasionally observed in response to PMA treatment. Therefore, 1
nmol/L calyculin A was used in the following experiments to prevent
rapid dephosphorylation of myofibrillar proteins.
Under basal conditions, addition of calphostin C (1 µmol/L)
for 3 minutes before the 10-minute incubation resulted in no reduction
in the 32P labeling of TnI compared with control cells.
There was also no apparent effect on the labeling of MLC2 (Fig 1
, lane
4). The enhanced phosphorylation of TnI in response to the addition of
1 µmol/L PMA was reversed (94.8±5.2% inhibition) in calphostin
Cpretreated myocytes (Fig 1
, lane 6). Similarly, enhanced
phosphorylation of MLC2 in response to PMA treatment was reduced
(84±6.5%) by calphostin C. Similar results were obtained in
populations of myocytes isolated from hearts of 11 different
animals.
Using rabbit anti-mouse MLC2 or a monoclonal antibody raised against
TnI as described in "Materials and Methods," we positively
identified the proteins phosphorylated by PMA as TnI and MLC2 by using
Western blot analysis (Fig 1
, lanes 7 and 8).
Phosphorylation of Cardiac Myofibrils by AA and ET
The addition of AA (50 µmol/L) for 10 minutes to
32P-labeled myocytes resulted in significant increases in
phosphorylation of TnI (30 kD) and MLC2 (20 kD) (Fig 3
,
lane 4), above the phosphorylation level observed in unstimulated
control cells (Fig 3
, lane 3). Similarly, the addition of ET (250
nmol/L) resulted in an increase in the labeling of TnI and MLC2 (Fig 3
,
lane 9) above unstimulated control cells. The addition of AA and ET
together resulted in a slight increase in the labeling of TnI
(9±4.3%) above that observed with either treatment alone (Fig 3
,
lanes 6 and 8), but this did not achieve statistical significance (n=6,
P<.08). Similarly, there was no significant effect of AA
and ET together on the labeling of MLC2 when compared with either
treatment alone. The results from six such experiments are summarized
in Fig 4
.
|
|
Effect of PKC Antagonist Calphostin C on Labeling of TnI and MLC2
by AA and/or ET
To determine if phosphorylation of TnI and MLC2 by AA and ET
occurred via activation of PKC, we incubated myocytes in the presence
of 1 µmol/L calphostin C for 10 minutes before the addition of AA,
ET, or AA and ET together (Fig 3
). Pretreatment of the myocytes with 1
µmol/L calphostin C, before stimulation with either AA, ET, or AA
plus ET, decreased the labeling of both TnI and MLC2 (Fig 3
).
Specifically, calphostin C reduced the labeling of TnI in response to
stimulation by AA, ET, or AA plus ET by >75% (Fig 3
, lanes 5, 7, and
10). Similarly, calphostin C blocked the increase in phosphorylation of
MLC2 by AA, ET, or AA plus ET by >90%. A summary of the results
obtained from six similar experiments is presented in Fig 4
.
Fura 2 Measurements of Intracellular Ca2+
Pools
Experiments were performed with isolated myocytes loaded with the
Ca2+-sensitive fluorescent indicator fura 2 to
measure cytosolic free Ca2+. These experiments were
performed to determine whether prolonged incubation (2 hours) of
cardiac myocytes in Ca2+-free HBS resulted in
depletion of intracellular Ca2+ stores, since we
planned to perform experiments examining the Ca2+
dependence of TnI and MLC2 phosphorylation by AA and ET. Cells
incubated in the presence of Ca2+ for 2 hours show
the presence of a large Ca2+ transient in response
to the addition of ionomycin, indicative of intact intracellular
Ca2+ stores (Fig 5
). In contrast,
cells incubated for 2 hours in the absence of extracellular
Ca2+ show a very small Ca2+
transient in response to ionomycin, which was only 10% to 15% of that
observed in cells exposed to HBS containing
Ca2+.
|
Effect of Extracellular Ca2+ and Intracellular
Ca2+ Stores on the Labeling of TnI and MLC2 by PMA,
AA, or ET
Incubation of cells in Ca2+-free HBS for 2
hours did not significantly affect the labeling of TnI by PMA, AA, or
ET compared with 32P labeling of TnI in myocytes that were
suspended in physiological concentrations of extracellular
Ca2+ (Fig 6
) and had intact
intracellular Ca2+ stores. Under similar conditions,
the labeling of MLC2 by PMA, AA, or ET in
Ca2+-depleted myocytes resuspended in
Ca2+-free HBS was not significantly different from
the extent of 32P labeling when compared with control
incubations in HBS containing Ca2+. A summary of
results from seven different myocyte preparations is shown in Fig 6
.
|
Effect of AA and ET on Myocyte Contractility
Superfusion of single field-stimulated ventricular myocytes with
AA (50 µmol/L) resulted in a 93±26% increase in the amplitude of
unloaded shortening above that observed before the addition of AA (Fig 7A
). A positive inotropic response was observed in
>80% of the cells examined (28 of 34 cells studied). Significant
increases in the amplitude of myocyte shortening were also observed
with concentrations of AA as low as 12.5 µmol/L and could be reversed
by superfusing the myocytes with HBS containing fatty acidfree bovine
serum albumin (10 µmol/L, data not shown). The increase in amplitude
of myocyte shortening typically reached a plateau within 4 minutes of
superfusion with AA. Superfusion of the myocytes with ET (250
nmol/L) resulted in a 71±21% (n=4 cells) increase in myocyte
shortening (Fig 7B
) and was much slower in onset compared with AA.
|
| Discussion |
|---|
|
|
|---|
In contrast to earlier studies using, primarily, reconstituted
myofibrils9 12 or permeabilized preparations of cardiac
myocytes10 11 to examine the effects of PMA- and/or
PKC-dependent activation on phosphorylation of contractile proteins, we
have investigated the effects of AA, ET, and PMA on phosphorylation of
contractile proteins in freshly isolated ventricular myocytes. In
addition, studies by other investigators9 10 11 12 have used a
mixture of isoforms of PKC isolated from mammalian brain that were
incubated with the permeabilized cardiac myocyte
preparation10 11 or reconstituted myofibrils9
in order to study PKC-dependent phosphorylation of cardiac
myofilaments. Therefore, isoforms of PKC that are prevalent in brain
(ie,
and ß isoforms) were present in the in vitro system;
however, these may be different from the primary isoform(s) present
in adult cardiac muscle cells.15 16 Thus, under these
conditions, one might observe protein phosphorylation that may not
necessarily occur in intact cells.
Phosphatase activity may play an important role in regulating the
phosphorylation state of both of these proteins, since higher doses of
calyculin A than those used in our experiments (10 nmol/L) stimulated
significant increases in the phosphorylation state of MLC2 and TnI in
cells that were not treated with agonist (Fig 2
). This indicates a
rapid turnover of phosphate in both of these proteins in situ, which
may play a significant regulatory role in cardiac contractile activity.
In fact, phosphatase inhibition with okadaic acid in guinea pig
papillary muscle has been demonstrated to induce phosphorylation of
myosin light chains, phospholamban, and TnI, resulting in a positive
inotropic effect.40 In contrast, a rapid acceleration in
phosphatase activity following phosphorylation reactions may rapidly
remove phosphate incorporated into myofibrillar proteins and may
explain the inability of other investigators to observe significant
increases in TnI phosphorylation following the addition of DG analogues
or PMA to isolated perfused hearts.41
The role of PKC-dependent phosphorylation of cardiac myofilaments in excitation-contraction coupling in cardiac muscle remains controversial. Phosphorylation of TnI in response to stimulation by phorbol esters in intact cardiac cells and reconstituted myofilaments resulted in a decrease in Vmax of actomyosin ATPase, with no shift in Ca2+ sensitivity.9 Previous studies in intact cardiac muscle cells or ventricular trabeculae have shown that stimulation by PMA or dioctanoylglycerol (DOG) results in a negative inotropic effect (decreased twitch amplitude) associated with either a decrease, or no change, in the sensitivity of the myofilaments to Ca2+, as well as a reduction in the amplitude of Ca2+ transients.20 42 Conversely, treatment of permeabilized cardiac muscle cells with PMA or DOG has been reported to increase Ca2+ sensitivity of force development10 and also to increase rate and amplitude of myocyte cell shortening.24 25 Therefore, the role of PMA and DOG as PKC activators and modulators of cardiac muscle cell function remains controversial. Recent reports that PMA can also activate mitogen-activated protein kinase,43 in addition to PKC, further complicate interpretation of these results. The presence of multiple PKC isoforms in cardiac muscle,14 44 TnI isoform switching,45 and developmental changes in PKC isoforms may also contribute to the observed differences.15
In addition to phosphorylation of TnI in cardiac muscle cells, AA and ET also stimulate a proportionally greater increase in phosphorylation of MLC2. Similar to phosphorylation of TnI, phosphorylation of MLC2 by AA or ET was inhibited by calphostin C. This suggested that incorporation of 32Pi into MLC2, in response to AA and ET stimulation, did not occur via activation of myosin light chain kinase but most likely via a PKC-dependent pathway. Therefore, phosphorylation of MLC2 by AA or ET may be involved in modulating cardiac contractility by increasing the sensitivity of the myofibrils to Ca2+ and/or by increasing maximal ATPase activity.10 12
Phosphorylation of MLC2 by PKC in rat cardiac myosin and reconstituted myofilaments has been shown to increase actomyosin ATPase activity; however, this effect was reversed by phosphorylation of TnI on the thin filament in a reconstituted model.12 In addition, studies showed that MLC2 phosphorylation increased the Ca2+ sensitivity of isometric force development of skinned ventricular fibers but had no influence on maximal shortening velocity.46 47 It has also been shown that the increased Ca2+ sensitivity of force development in skinned cardiac muscle cells following MLC2 phosphorylation by myosin light chain kinase could be further enhanced by the addition of PKC.10 Similarly, maximal Ca2+-activated actomyosin ATPase activity was elevated in the presence of myosin light chain kinase and increased further in the presence of both myosin light chain kinase and PKC.10 Therefore, increases in MLC2 phosphorylation following stimulation by ET or AA may result in increased sensitivity of the myofilaments to Ca2+ and/or increased ATPase activity and may explain, in part, the increase in contractility in rat cardiac myocytes in response to AA and ET in the present study.48 49 However, it is possible that inhibition of K+ channels by AA or ET,2 resulting in action potential prolongation and enhanced Ca2+ entry, may also play an important role in the modulation of contractility observed in response to AA and ET in the present study.
We also investigated whether there was an additive effect of AA and ET on phosphorylation of TnI and MLC2. Treating the myocytes with AA and ET together resulted in no significant increase in phosphorylation of TnI or MLC2 above that observed after stimulation with either agonist alone, suggesting that both MLC2 and TnI are most likely phosphorylated at the same site in response to stimulation by both AA and ET. Future experiments using two-dimensional gel electrophoresis of tryptic digests of 32P-labeled cardiac myofilaments will be required to confirm this idea.
Despite effective depletion of the intracellular pools of
Ca2+ (as judged by a significant decrease in the
size of the ionomycin-releasable Ca2+ pool) and the
absence of extracellular Ca2+, PMA, AA, and
ET all stimulated phosphorylation of TnI and MLC2 to a similar degree,
as observed in cells with intact intracellular Ca2+
stores suspended in buffer containing 1.2 mmol/L
Ca2+. These results thus indicate that
Ca2+ influx and/or intracellular
Ca2+ mobilization is not required for
phosphorylation of MLC2 or TnI by AA or ET. These data also suggest
that activation of myosin light chain kinase, known to be dependent on
an increase in Ca2+ and the presence of calmodulin,
is most likely not involved in mediating phosphorylation of TnI and
MLC2 in rat cardiac myocytes in response to AA, ET, or PMA. It is
possible that phosphorylation of TnI and MLC2 in response to AA and/or
ET is mediated via activation of a Ca2+-insensitive
isoform of PKC, potentially PKC-
, since Bogoyevitch et
al16 have shown that phorbol esters and ET stimulation
results in translocation of PKC-
to the membrane in adult rat
cardiac myocytes.
In the intact cell, physiological agonists are likely to trigger many signaling pathways that modulate cellular events. Therefore, it is important to assess the functional significance of stimulation at the level of the whole cell rather than just at the level of the myofilaments. In the present study, we found that addition of both AA and ET separately to single electrically stimulated myocytes resulted in a positive inotropic effect, as evidenced by an increase in amplitude of myocyte shortening. Other investigators have also obtained similar results with ET.48 49
The positive inotropic effect of AA may be attributable to an increase in the phosphorylation of TnI and/or MLC2, as described in the present study, and/or to increased Ca2+ entry as a result of inhibition of Ito, as described in our earlier study.2 However, preliminary studies on electrically stimulated Ca2+ transients in single myocytes indicate no increase in the amplitude of the cytosolic Ca2+ transient during superfusion of isolated cells with AA (D.S. Damron, B. Summers, M. Bond, unpublished data, 1994). Therefore, it is likely that the increase in amplitude of shortening observed in response to AA stimulation may be attributable primarily to an increase in the sensitivity of the myofilaments to Ca2+ following phosphorylation of MLC2 and/or TnI.
In conclusion, we have shown that in intact cardiac myocytes, AA and ET stimulate phosphorylation of TnI and MLC2 via Ca2+-insensitive pathways that are inhibited by calphostin C. These results also suggest that AA and ET may activate the same Ca2+-independent isoform of PKC in intact cardiac muscle cells, since both agents phosphorylate the same myofibrillar proteins and since the increase in phosphorylation of MLC2 or TnI in response to maximal concentrations of AA and ET is similar in magnitude and not additive.
Activation of Ca2+-independent PKC isoforms by physiological agonists may be important for transduction of signals that modulate cardiac contractility, since Ca2+ is continually cycling in cardiac muscle cells in vivo. These results demonstrate for the first time that AA enhances the contractility of individual muscle cells, which may be mediated, in part, by phosphorylation of the myofibrillar proteins TnI and MLC2.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received August 22, 1994; accepted February 28, 1995.
| References |
|---|
|
|
|---|
2.
Damron DS, Van Wagoner DR, Moravec CS, Bond M.
Arachidonic acid and endothelin potentiate
Ca2+ transients in rat cardiac myocytes via
inhibition of distinct K+ channels. J
Biol Chem. 1993;268:27335-27344.
3. Kim RS, La Bella FS. The effect of linoleic and arachidonic acid derivatives on calcium transport in vesicles isolated from cardiac sarcoplasmic reticulum. J Mol Cell Cardiol. 1988;20:119-130.
4.
Kim D, Duff R. Regulation of K+
channels in cardiac myocytes by free fatty acids.
Circ Res. 1990;67:1040-1046.
5.
Huang JMC, Xian H, Bacaner M. Long-chain fatty
acids activate calcium channels in ventricular myocytes.
Proc Natl Acad Sci U S A. 1992;89:6452-6456.
6.
Shubeita HE, McDonough PM, Harris AN, Knowlton
KU, Glembotski CC, Brown JH, Chien KR. Endothelin induction of
inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene
expression in ventricular myocytes. J Biol Chem. 1990;265:20555-20562.
7. Prasad MR. Endothelin stimulates degradation of phospholipids in isolated rat hearts. Biochem Biophys Res Commun. 1991;174:952-957. [Medline] [Order article via Infotrieve]
8. Seifert R, Schachtele C, Schultz G. Activation of protein kinase C by cis- and trans-octadecadienoic acids in intact human platelets and its potentiation by diacylglycerol. Biochem Biophys Res Commun. 1987;149:762-768. [Medline] [Order article via Infotrieve]
9.
Venema R, Kuo JF. Protein kinase C-mediated
phosphorylation of troponin I and C-protein in isolated myocardial
cells is associated with inhibition of myofibrillar actomyosin
MgATPase. J Biol Chem. 1993;268:2705-2711.
10. Clement O, Puceat M, Walsh MP, Vassort G. Protein kinase C enhances myosin light chain kinase effects on force development and ATPase activity in rat single skinned cardiac cells. Biochem J. 1992;285:311-317.
11.
Puceat M, Clement O, Lechene P, Pelosin JM,
Ventura-Clapier R, Vassort G. Neurohumoral control of calcium
sensitivity of myofilaments in rat single heart cells.
Circ Res. 1990;67:517-524.
12. Noland TA, Kuo JF. Phosphorylation of cardiac myosin light chain 2 by protein kinase C and myosin light chain kinase increases Ca2+-stimulated actomyosin MgATPase activity. Biochem Biophys Res Commun. 1993;193:254-260. [Medline] [Order article via Infotrieve]
13. Mochly-Rosen D, Henrich CJ, Cheever L, Kahner H, Simpson PC. A protein kinase C isozyme is translocated to cytoskeletal elements on activation. Cell Regul. 1990;1:693-706. [Medline] [Order article via Infotrieve]
14. Disatnik MH, Buraggi G, Mochly-Rosen D. Localization of protein kinase C isozymes in cardiac myocytes. Exp Cell Res. 1994;210:287-297. [Medline] [Order article via Infotrieve]
15.
Rybin VO, Steinberg SF. Protein kinase C isoform
expression and regulation in the developing rat heart.
Circ Res. 1994;74:299-309.
16.
Bogoyevitch MA, Parker PJ, Sugden PH.
Characterization of protein kinase C isotype expression in adult
rat heart: protein kinase C-
is a major isotype present, and it
is activated by phorbol esters, epinephrine, and endothelin.
Circ Res. 1993;72:757-767.
17.
Chien KR, Han A, Sen A, Buja LM, Willerson JT.
Accumulation of unesterified arachidonic acid in ischemic canine
myocardium: relationship to phosphatidylcholine deacylation-reacylation
cycle and the depletion of membrane phospholipids.
Circ Res. 1984;54:313-322.
18.
Liu J, Chen R, Casley D, Nayler WG. Ischemia and
reperfusion increase 125I-labeled endothelin-1 binding in
rat cardiac membranes. Am J Physiol (Lond). 1990;258:H829-H835.
19. Prasad MR, Jones RM. Enhanced membrane protein kinase C activity in myocardial ischemia. Basic Res Cardiol. 1992;87:19-26. [Medline] [Order article via Infotrieve]
20.
Capogrossi MC, Kaku T, Filburn CR, Pelto DJ, Hansford
RG, Spurgeon HA, Lakatta EG. Phorbol ester and
dioctanoylglycerol stimulate membrane association of protein kinase C
and have a negative inotropic effect mediated by changes in cytosolic
Ca2+ in adult rat cardiomyocytes.
Circ Res. 1990;66:1143-1155.
21.
Watson JE, Karmazyn M. Concentration-dependent
effects of protein kinase Cactivating and nonactivating phorbol
esters on myocardial contractility, coronary resistance, energy
metabolism, prostacyclin synthesis, and ultrastructure in isolated rat
hearts: effects of amiloride. Circ Res. 1991;69:1114-1131.
22. Moravec CS, Reynolds EE, Stewart RW, Bond M. Endothelin is a positive inotropic agent in human and rat heart in vitro. Biochem Biophys Res Commun. 1989;159:14-18. [Medline] [Order article via Infotrieve]
23. Terzic A, Puceat M, Vassort G, Vogel S. Cardiac alpha-1 adrenoreceptors: an overview. Pharmacol Rev. 1993;45:147-175. [Medline] [Order article via Infotrieve]
24.
MacLeod KT, Harding SE. Effects of phorbol ester
on contraction, intracellular pH and intracellular
Ca2+ in isolated mammalian ventricular
myocytes. J Physiol (Lond). 1990;444:481-498.
25. Ward CA, Moffat MP. Positive and negative inotropic effects of phorbol 12-myristate 13-acetate: relationship to PKC-dependence and changes in [Ca2+]i. J Mol Cell Cardiol. 1992;24:937-948. [Medline] [Order article via Infotrieve]
26. Lacerda AE, Rampe D, Brown AM. Effects of protein kinase activators of cardiac Ca2+ channels. Nature. 1988;335:249-251. [Medline] [Order article via Infotrieve]
27.
Movsesian MA, Nishikawa M, Adelstein RS.
Phosphorylation of phospholamban by calcium-activated
phospholipid-dependent protein kinase. J Biol Chem. 1984;259:8029-8032.
28.
Takasago T, Imagawa T, Furukawa K, Orurusu T, Shigekawa
M. Regulation of the cardiac ryanodine receptor by protein
kinase-dependent phosphorylation. J Biochem. 1990;109:163-170.
29. Limas CJ. Phosphorylation of cardiac sarcoplasmic reticulum by a calcium-activated, phospholipid-dependent protein kinase. Biochem Biophys Res Commun. 1980;96:1378-1383. [Medline] [Order article via Infotrieve]
30. Takuwa Y, Kasuya Y, Takuwa N, Kudo M, Yanagisawa M, Goto K, Masaki T, Yamashita K. Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells. J Clin Invest. 1990;85:653-658.
31. Altschuld R, Gibb L, Zoretic A, Hohl C, Kruger F, Brierley GP. Calcium tolerance of isolated rat heart cells. J Mol Cell Cardiol. 1980;12:1383-1395. [Medline] [Order article via Infotrieve]
32.
Onorato JJ, Rudolph SA. Regulation of protein
phosphorylation by inotropic agents in isolated rat myocardial
cells. J Biol Chem. 1981;256:10697-10703.
33. Kobayashi E, Nakano H, Morimoto M, Tamaoki T. Calphostin C, (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1989;159:548-553. [Medline] [Order article via Infotrieve]
34. Ishihara H, Martin BL, Brautigan DL, Karaki H, Ozaki H, Kato Y, Fusetani N, Watabe S, Hashimoto K, Uemura D, Hartshorne DJ. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun. 1989;159:871-877. [Medline] [Order article via Infotrieve]
35. Holroyde MJ, Small DAP, Howe E, Solaro RJ. Isolation of cardiac myofibrils and myosin light chains with in vivo levels of light chain phosphorylation. Biochem Biophys Acta. 1979;587:628-637. [Medline] [Order article via Infotrieve]
36. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685. [Medline] [Order article via Infotrieve]
37.
Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ.
Protein measurements with the folin phenol reagent.
J Biol Chem. 1951;193:265-275.
38. Burnette WN. Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981;112:195-203. [Medline] [Order article via Infotrieve]
39. Venema RC, Raynor RL, Noland TA, Kuo JF. Role of protein kinase C in the phosphorylation of cardiac myosin light chain 2. Biochem J. 1993;294:401-406.
40.
Neumann J, Boknik P, Herzig S, Schmitz W, Scholz H,
Gupta RC, Watanabe AM. Evidence for physiological functions of
protein phosphatases in the heart: evaluation with okadaic
acid. Am J Physiol. 1993;265:H257-H266.
41.
Edes I, Kranias EG. Phospholamban and troponin I
are substrates for protein kinase C in vitro but not in intact beating
guinea pig hearts. Circ Res. 1990;67:394-400.
42.
Gwathmey JK, Hajjar RJ. Effect of protein kinase
C activation on sarcoplasmic reticulum function and apparent
myofibrillar Ca2+ sensitivity in intact and skinned
muscles from normal and diseased human myocardium.
Circ Res. 1990;67:744-752.
43.
Sadoshima J, Qiu Z, Morgan JP, Izumo S.
Angiotensin II and other hypertrophic stimuli mediated by G
proteincoupled receptors activate tyrosine kinase, mitogen-activated
protein kinase, and 90-kD S6 kinase in cardiac myocytes: the critical
role of Ca2+-dependent signaling.
Circ Res. 1995;76:1-15.
44.
Kohout TA, Rogers TB. Use of polymerase chain
reaction-based method to characterize protein kinase C isoform
expression in cardiac cells. Am J Physiol. 1993;264:C1350-C1359.
45.
Martin AF, Ball K, Gao L, Kumar P, Solaro RJ.
Identification and functional significance of troponin I
isoforms in neonatal rat heart myofibrils. Circ
Res. 1991;69:1244-1252.
46. Morano I, Hofmann F, Zimmer M, Ruegg J-C. The influence of P-light chain phosphorylation by myosin light chain kinase on the calcium sensitivity of chemically skinned heart fibers. FEBS Lett. 1985;189:221-224. [Medline] [Order article via Infotrieve]
47.
Sweeney HL, Stull JT. Phosphorylation of myosin
in permeabilized mammalian cardiac and skeletal muscle cells.
Am J Physiol. 1986;250:C657-C660.
48.
Krämer BK, Smith TW, Kelly RA. Endothelin
and increased contractility in adult rat ventricular myocytes: role of
intracellular alkalosis induced by activation of the protein kinase
Cdependent Na+-H+ exchanger.
Circ Res. 1990;68:269-279.
49. Kelly RA, Eid H, Kramer BK, O'Neill M, Liang BT, Reers M, Smith TW. Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway. J Clin Invest. 1990;86:1164-1171.
This article has been cited by other articles:
![]() |
A. Molnar, A. Borbely, D. Czuriga, S. M. Ivetta, S. Szilagyi, Z. Hertelendi, E. T. Pasztor, A. Balogh, Z. Galajda, T. Szerafin, et al. Protein Kinase C Contributes to the Maintenance of Contractile Force in Human Ventricular Cardiomyocytes J. Biol. Chem., January 9, 2009; 284(2): 1031 - 1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hlavackova, J. Neckar, J. Jezkova, P. Balkova, B. Stankova, O. Novakova, F. Kolar, and F. Novak Dietary Polyunsaturated Fatty Acids Alter Myocardial Protein Kinase C Expression and Affect Cardioprotection Induced by Chronic Hypoxia Experimental Biology and Medicine, June 1, 2007; 232(6): 823 - 832. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Westfall, A. M. Lee, and D. A. Robinson Differential Contribution of Troponin I Phosphorylation Sites to the Endothelin-modulated Contractile Response J. Biol. Chem., December 16, 2005; 280(50): 41324 - 41331. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. D Russell and P. Molenaar Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart Cardiovasc Res, September 1, 2004; 63(4): 673 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Goldspink, D. E. Montgomery, L. A. Walker, D. Urboniene, R. D. McKinney, D. L. Geenen, R. J. Solaro, and P. M. Buttrick Protein Kinase C{epsilon} Overexpression Alters Myofilament Properties and Composition During the Progression of Heart Failure Circ. Res., August 20, 2004; 95(4): 424 - 432. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Metzger and M. V. Westfall Covalent and Noncovalent Modification of Thin Filament Action: The Essential Role of Troponin in Cardiac Muscle Regulation Circ. Res., February 6, 2004; 94(2): 146 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kan, Z. Xie, and M. S. Finkel p38 MAP kinase-mediated negative inotropic effect of HIV gp120 on cardiac myocytes Am J Physiol Cell Physiol, January 1, 2004; 286(1): C1 - C7. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Pi, D. Zhang, K. R Kemnitz, H. Wang, and J. W Walker Protein kinase C and A sites on troponin I regulate myofilament Ca2+ sensitivity and ATPase activity in the mouse myocardium J. Physiol., November 1, 2003; 552(3): 845 - 857. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Westfall and A. R. Borton Role of Troponin I Phosphorylation in Protein Kinase C-mediated Enhanced Contractile Performance of Rat Myocytes J. Biol. Chem., September 5, 2003; 278(36): 33694 - 33700. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G. Pyle, M. P. Sumandea, R. J. Solaro, and P. P. De Tombe Troponin I serines 43/45 and regulation of cardiac myofilament function Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H1215 - H1224. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Pi, K. R. Kemnitz, D. Zhang, E. G. Kranias, and J. W. Walker Phosphorylation of Troponin I Controls Cardiac Twitch Dynamics: Evidence From Phosphorylation Site Mutants Expressed on a Troponin I-Null Background in Mice Circ. Res., April 5, 2002; 90(6): 649 - 656. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mackay and D. Mochly-Rosen Arachidonic acid protects neonatal rat cardiac myocytes from ischaemic injury through {epsilon} protein kinase C Cardiovasc Res, April 1, 2001; 50(1): 65 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T Rapundalo Cardiac protein phosphorylation: functional and pathophysiological correlates Cardiovasc Res, June 1, 1998; 38(3): 559 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Pawloski-Dahm, G. Song, D. L. Kirkpatrick, J. Palermo, J. Gulick, G. W. Dorn II, J. Robbins, and R. A. Walsh Effects of Total Replacement of Atrial Myosin Light Chain-2 With the Ventricular Isoform in Atrial Myocytes of Transgenic Mice Circulation, April 21, 1998; 97(15): 1508 - 1513. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Redaelli, A. Malhotra, B. Li, P. Li, E. H. Sonnenblick, P. A. Hofmann, and P. Anversa Effects of Constitutive Overexpression of Insulin-Like Growth Factor-1 on the Mechanical Characteristics and Molecular Properties of Ventricular Myocytes Circ. Res., March 23, 1998; 82(5): 594 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Starkopf, T. V Andreasen, E. Bugge, and K. Ytrehus Lipid peroxidation, arachidonic acid and products of the lipoxygenase pathway in ischaemic preconditioning of rat heart Cardiovasc Res, January 1, 1998; 37(1): 66 - 75. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Malhotra, D. Reich, D. Reich, A. Nakouzi, V. Sanghi, D. L. Geenen, and P. M. Buttrick Experimental Diabetes Is Associated With Functional Activation of Protein Kinase C{epsilon} and Phosphorylation of Troponin I in the Heart, Which Are Prevented by Angiotensin II Receptor Blockade Circ. Res., December 19, 1997; 81(6): 1027 - 1033. [Abstract] [Full Text] |
||||
![]() |
A. Sauvadet, T. Rohn, F. Pecker, and C. Pavoine Arachidonic Acid Drives Mini-glucagon Action in Cardiac Cells J. Biol. Chem., May 9, 1997; 272(19): 12437 - 12445. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Malhotra and V. Sanghi Regulation of contractile proteins in diabetic heart Cardiovasc Res, April 1, 1997; 34(1): 34 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Huang, Y Pi, A. Lokuta, M. Greaser, and J. Walker Arachidonic acid stimulates protein kinase C-epsilon redistribution in heart cells J. Cell Sci., January 7, 1997; 110(14): 1625 - 1634. [Abstract] [PDF] |
||||
![]() |
B.-X. Zhang, X. Ma, B. K. McConnell, D. S. Damron, and M. Bond Activation of Purinergic Receptors Triggers Oscillatory Contractions in Adult Rat Ventricular Myocytes Circ. Res., July 1, 1996; 79(1): 94 - 102. [Abstract] [Full Text] |
||||
![]() |
Y. Pi, K. R. Kemnitz, D. Zhang, E. G. Kranias, and J. W. Walker Phosphorylation of Troponin I Controls Cardiac Twitch Dynamics: Evidence From Phosphorylation Site Mutants Expressed on a Troponin I-Null Background in Mice Circ. Res., April 5, 2002; 90(6): 649 - 656. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |